• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed

    1/12/21 4:15:16 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PTE alert in real time by email
    SC 13D/A 1 p21-0015sc13da.htm POLARITYTE, INC.
    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D/A
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
    RULE 13d-2(a)
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
     

    PolarityTE, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    731094108

    (CUSIP Number)
     
    Liad Meidar
    Gatemore Capital Management LLP
    33 Cavendish Square
    London W1G 0PW
    +44 (0) 207 580 0300
     
    Aneliya Crawford
    Schulte Roth & Zabel LLP
    919 Third Avenue
    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    January 8, 2021

    (Date of Event Which Requires Filing of This Statement)
     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [ ]

    (Page 1 of 5 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the

    liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 731094108SCHEDULE 13D/APage 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    Gatemore Capital Management LLP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    2,928,753 shares of Common Stock

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    2,928,753 shares of Common Stock

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    2,928,753 shares of Common Stock

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    4.9%

    14

    TYPE OF REPORTING PERSON

    IA, PN

             

     

     

    CUSIP No. 731094108SCHEDULE 13D/APage 3 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    Liad Meidar

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    2,928,753 shares of Common Stock

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    2,928,753 shares of Common Stock

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    2,928,753 shares of Common Stock

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    4.9%

    14

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 731094108SCHEDULE 13D/APage 4 of 5 Pages

     

    The following constitutes Amendment No. 3 to the Schedule 13D filed by the undersigned ("Amendment No. 3"). This Amendment No. 3 amends the Schedule 13D as specifically set forth herein. Capitalized terms used herein and not otherwise defined in this Amendment No. 3 have the meanings set forth in the Schedule 13D.

     

    Item 4. PURPOSE OF TRANSACTION
       
      Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following:
       
      On January 8, 2021, the Gatemore Fund submitted a letter to the Issuer, demanding production of certain of the Issuer’s books and records pursuant to Section 220 of the General Corporation Law of the State of Delaware in connection with the Board's sanctioning of two highly dilutive public offerings implemented without shareholder approval and in a manner which the Gatemore Fund believes was in dereliction of the Board's fiduciary duties.

     

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER
       
      Items 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:
       
    (a) See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of and percentages of the shares of Common Stock beneficially owned by each Reporting Person. The percentages set forth in this Schedule 13D are based upon 60,132,822 shares of Common Stock outstanding as of January 8, 2021, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 11, 2021.
       
    (b) See rows (7) through (10) of the cover pages to this Schedule 13D for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
       
    (c) There have been no transactions in the shares of Common Stock effected by the Reporting Persons in the last sixty days.
       
    (e) Not applicable.

     

     

     

     

    CUSIP No. 731094108SCHEDULE 13D/APage 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: January 12, 2021

     

      GATEMORE CAPITAL MANAGEMENT LLP
       
       
      By: /s/ Liad Meidar
      Name:  Liad Meidar
      Title:    Managing Partner
       
       
       
       
      /s/ Liad Meidar
      LIAD MEIDAR

     

     

    Get the next $PTE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PTE
    SEC Filings

    View All

    PolarityTE Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - POLARITYTE, INC. (0001076682) (Filer)

    8/18/23 4:54:40 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form NT 10-Q filed by PolarityTE Inc.

    NT 10-Q - POLARITYTE, INC. (0001076682) (Filer)

    8/15/23 4:40:32 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PolarityTE Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    8-K - POLARITYTE, INC. (0001076682) (Filer)

    8/15/23 4:30:36 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company

    SALT LAKE CITY, Dec. 27, 2022 /PRNewswire/ --  PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials (the "Company"), today announced that it signed a non-binding letter of intent (the "LOI") with Michael Brauser ("Brauser") for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash. As of December 23, 2022, there were 7,256,786 shares of the Company's common stock outstanding and unvested restricted stock units covering an additional 256,457 common shares. 

    12/27/22 8:30:00 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update

    SALT LAKE CITY, Nov. 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022. Recent Business and Financial UpdatesAt the end of April 2022, PolarityTE began enrollment in its Phase III randomized controlled trial (RCT), which is a pivotal study under its open IND for SkinTE®. The Company estimates that it may be able to complete enrollment of 100 subjects sometime in the first six mon

    11/10/22 4:30:00 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company

    SALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash. The offer is subject to various contingencies, including, among others, (1) settlement with warrant holders and satisfactory negotiations with insiders with change of control agreements, (2) minimum tender conditions, (3) a sixty-day due diligence period, and (4) satisfacti

    11/9/22 8:00:00 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Dyer Jeffrey Hansen was granted 42,986 shares, increasing direct ownership by 3,177% to 44,339 units

    4 - POLARITYTE, INC. (0001076682) (Issuer)

    1/30/23 4:30:42 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3: New insider Dyer Jeffrey Hansen claimed ownership of 1,353 shares

    3 - POLARITYTE, INC. (0001076682) (Issuer)

    1/30/23 4:15:33 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Nolet Chris decreased direct ownership by 72% to 14,403 units

    4 - POLARITYTE, INC. (0001076682) (Issuer)

    1/17/23 4:30:29 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by PolarityTE Inc. (Amendment)

    SC 13G/A - POLARITYTE, INC. (0001076682) (Subject)

    2/14/23 11:11:43 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by PolarityTE Inc.

    SC 13G - POLARITYTE, INC. (0001076682) (Subject)

    8/23/22 11:30:24 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed

    SC 13G - POLARITYTE, INC. (0001076682) (Subject)

    2/16/21 5:19:31 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTE
    Financials

    Live finance-specific insights

    View All

    PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update

    PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET SALT LAKE CITY, Aug. 11, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended June 30, 2022. Recent Business and Financial UpdatesIn January 2022, PolarityTE was advised by the U.S. Food and Drug Administration (FDA) that it could conduct human clinical trials under PolarityTE's investigational new drug application (IND

    8/11/22 4:05:00 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PolarityTE to Report Q2 2022 Financial Results on August 11, 2022

    SALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on August 11, 2022, at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-800-207-0148 with passcode 893469 and referencing "PolarityTE Second Quarter 2022 Business Update and Financial Results." A webcast of the conference call can be accesse

    8/1/22 8:00:00 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Polarity TE spins off IBEX Preclinical Research contract research organization

    Dr. Josh Packer acquires IBEX and becomes CEO; maintains existing surgical research team LOGAN, Utah, May 26, 2022 /PRNewswire-PRWeb/ -- IBEX Preclinical Research, Inc., a trusted outsourcing partner and provider of preclinical surgical and toxicological studies in a variety of laboratory animal species, announced that it has been acquired by Josh Packer, DVM. IBEX provides in-vivo research services ranging from relatively simple single-dose pharmacokinetic studies to more complex projects requiring surgical instrumentation. Conducting both GLP and non-GLP non-clinical testing, IBEX supports life science, medical device companies and researchers that specialize in orthopedics, neurosurgical,

    5/26/22 11:15:00 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTE
    Leadership Updates

    Live Leadership Updates

    View All

    PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors

    SALT LAKE CITY, Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately. "On behalf of our Board and PolarityTE's management team, we thank Jeff for his service and longstanding commitment to the Company," stated Richard Hague, Chief Executive Officer of PolarityTE.  "We greatly appreciate the leadership and insight that Jeff has provided over the past five and a half years as we purs

    9/8/22 8:30:00 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

    SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

    2/23/21 4:05:00 PM ET
    $VIE
    $PTE
    $RVNC
    Major Pharmaceuticals
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations